Sarah Cannon Research Institute (SCRI) is a research organization focusing on therapies for patients including drug development. With corporate headquarters in Nashville, Tennessee, United States, it conducts community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas. The current CEO is Dee Anna Smith. SCRI accrued more than 2,500 patients to cancer trials in 2009, including more than 500 to Phase I investigational studies. Non-oncology trials accounted for nearly 1,500 additional patients for a total of almost 4,000. Its drug development program has conducted 70+ “first-in-man” trials. SCRI has been involved in the testing and development of about 10 drugs that have been approved since 1999.